Abstract Denmark is a society that has already moved towards Big Data and a Learning Health Care System. Data from routine healthcare has been registered centrally for years, there is a nationwide tissue bank, and there are numerous other available registries about education, employment, housing, pollution, etcetera. This has allowed Danish researchers to study the link between exposures, genetics and diseases in a large population. This use of public registries for scientific research has been relatively uncontroversial and has been supported by facilitative regulation that allows data to be used without the consent of data subjects. However, in the future much of the data will not be held by public authorities but by private companies. What are the implications of this shift for the governance of the research use of the data? This paper will argue that increased involvement of Research Ethics Committees and better training of researchers are necessary; and that some form of consent will have to be re-introduced. Four different consent models will be discussed: Opt-Out, Broad/Blanket consent, Dynamic consent, and Meta consent. It will be argued that a governance model including a possibility for citizens to make metachoices strikes the best balance between individual and public interests.
Introduction
The vision of health improvement through the analysis of Big Data within the context of a Learning Health Care System is a powerful driver for the collection and sharing of health data and for considerations concerning whether traditional consent requirements for the secondary use of data should be relaxed in this context (Institute of Medicine Committee on the Learning Health Care System in America 2013; Information Commissioner's Office 2014).
Denmark has already moved far in the direction of Big Data research in healthcare and has a very liberal governance regime for such research. It therefore provides a valuable case study for analysing future developments and governance needs. In this paper we especially focus on a future mixed economy of data where we have moved from the current situation where most of the data used in research comes from public authorities, to a situation where a significant proportion of the data comes from commercial actors.
The paper falls in three parts. First we describe the current Danish situation and the societal, legal, health system, and research developments that brought it into being, and briefly describe some examples of the major research successes that have resulted from easy access to health data and easy and non-ambiguous cross linking of health data to other data. Second, we briefly outline a likely development in the near future where the data used and analysed are no longer just data held by the healthcare system or other public authorities but where data held by private, commercial companies becomes important for research. Third, we discuss whether the current Danish governance system for the secondary research use of health data is still suitable in the context of a future mixed data economy. We argue that the current governance system is ill suited to deal with extensive use of commercial data and that issues of consent are re-actualized. We discuss four different consent models that all have strengths and weaknesses but argue that a governance model including a possibility for citizens to make meta-choices about the use of their data is the best option. It is strongly supported by ethical argument and also practically implementable.
Although the focus is on Denmark and the Danish situation, most of our analyses and arguments are more broadly applicable. Our critical arguments are very widely applicable, and our constructive arguments and suggestions are likely to be applicable in contexts in which there is a high degree of general trust in healthcare institutions and health researchers.
Data Heaven
Denmark is the embodiment of the epidemiologist's dream-a society which has already moved far in the direction of Big Data and is already well on its way to implement a Learning Health Care System. Denmark introduced a national Central Personal Registry (CPR) number in 1968 that uniquely identifies each person who is resident in Denmark. Most Danes know their CPR number by heart, and it is used for identification whenever public authorities collect information about the citizens, as well as for a wide range of private transactions (it is, for instance used for identification in relation to all bank accounts and personal insurance contracts as well as mobile phone contracts and many other things).
Healthcare information is routinely collected every time a citizen is in contact with the healthcare system and entered into centralized databases. This data collection activity has been going on for a long time. To give some examples: The hospital episode registry has been operating since 1976, the cancer registry since 1942-3, the abortion registry since 1973, the prescription registry since 1994, and the cause of death registry in its electronic form since 1970. There are also more than seventy more structured, so-called clinical quality databases where more detailed information about a particular intervention (e.g. hip replacement) or a particular patient group (e.g. patients in treatment for multiple sclerosis) is registered on pre-defined registration forms developed specifically for each intervention/patient group. The primary purpose of these clinical quality databases is to form the basis for audit and quality improvement, but they are also very useful for research since the data quality is better than in the general databases and the available data much more detailed. Many of the clinical quality databases collaborate with similar databases in the other Nordic countries to ensure interoperability and to make it possible to combine data to create larger virtual Nordic databases (Havelin et al. 2011) .
Danish general practitioners all use electronic record systems and full electronic patient records are currently being implemented in Danish hospitals. It is predictable that these electronic patient records, or at the very least rich, standardized datasets extracted and text mined from them, will become available for research use in the not-too-distant future. Such use is already taking place at a local scale, but there is not yet a national registry of these data.
Most people will be unaware of the extent to which their health data is routinely collected and stored, and there are no consent requirements for the collection. There is, furthermore, no right to have data withdrawn from these databases because they are primarily established to support administration and planning in the healthcare system or as the basis for audit and quality control activities. A right to withdrawal would also in practice be illusory because of the general ignorance mentioned above and because data subjects are not informed when their data is used for research.
All of the health databases are as close to being as complete as is possible, and using them in research therefore eliminates risks of ascertainment or recall bias.
Almost all the public health registries are held by one body, Sundhedsdatastyrelsen (the Health Data Board) and Danish researchers can access them in a one stop shop through the Board's Forskerservice (Researcher Service). Access is available both to researchers working in universities and other public institutions and to researchers working for commercial firms. Researchers can order specific cross-linked datasets, or they can perform their analysis remotely on the Board's virtual Researcher Machine. The datasets that researchers are provided with, or have access to through the Researcher Machine, are de-identified (but see below about access to identifiable data).
Health data can be cross-linked to a wide variety of other data. Danmarks Statistik (Statistics Denmark) collects a very wide range of individual level sociodemographic data including data on place of residence, type and size of residence, marital status, educational achievement, employment status and salary, and much more. Denmark also still has military conscription for male citizens and data on the physical characteristics, health status, and intelligence tests of all eighteen-yearold males is collected during the compulsory preconscription assessment and stored in the conscription registry. All of these databases use the CPR number as the identifier and can be easily and non-ambiguously cross-linked to health data or to area based data (e.g. various forms of pollution data).
Danish epidemiological research developed early, partly because of the investments of the Rockefeller Foundation into medical research and what would probably today be called genetic epidemiology in Copenhagen in the 1920s and 1930s (Rasmussen 1998) ; and the routine use of health and social data for research was already well entrenched prior to the introduction of the first Research Ethics Committees (RECs) in 1976 and the introduction of research ethics legislation in 1992 (Holm 1992; Rossel 2017) . The fact that research use of health data was already routine before the research governance system was put in place explains some of the features of the Danish system.
The first Danish legislation on research ethics was passed in 1992 and required research ethics committee (REC) approval of projects using data from the health registries (L 503 1992, §6.2). However, the legislation explicitly exempted registry-based research from any consent requirements, except in exceptional cases where the REC decided to impose a consent requirement (L503 1992, §8.3). The requirement for REC approval for research only involving registry data was abolished in 1996 (L499 1996). Registry-based research still has to conform to the Danish Data Protection Act (L429 2000), and registry-based research has to be approved by the Danish Data Protection Authority. There is no consent requirement, and the approval is based on an Bobjective evaluation^in the legal sense, i.e. solely concerned with whether 1) the project is legal according to the Act, 2) there is adequate data security, and 3) the applicant is a bona fide researcher. In the approval process at the Data Protection Authority considerations concerning possible harms to data subjects or relating to the sensitivity of the research questions are irrelevant. If researchers need access to identifiable data, for instance to validate diagnostic codes for individual cases, they can seek permission from the Data Protection Authority to access such data and if permission is granted access will still not require consent from or notification of the data subjects.
Apart from the databases described above Denmark also has an open access National Biobank Registry that holds information about accessible tissue samples from 5.4 million individuals.
1 Access to and use of these tissue samples for research requires REC approval of the project but not consent from the original tissue donors. And, when data has been extracted from a tissue sample, for instance by full genome sequencing, such data can then be used in future projects without REC approval or consent.
Denmark thus has one of the most, perhaps even the most, liberal governance regimes for secondary research use of health and other data. The Danish governance system is, for instance, immensely more liberal than the one in the United Kingdom (e.g. compare with the description of the U.K. situation in Laurie and Stevens 2016) . What further sets the Danish system apart is that it is liberal by intention and not for instance as a byproduct of a lack of regulation. Danish political decision-makers have deliberately and explicitly designed the legal regulations in this way.
The registration of this vast range and amount of data and its later secondary use for research purposes seems to have been tacitly accepted by Danish society, and there has been relatively little public discussion of issues of consent for collection and use or of the governance arrangements implemented in this area. Even the recent revelation that the complete, non-anonymized hospital episode database was routinely posted on unencrypted CD-ROMs from the predecessor to the Health Data Board to Statistics Denmark and that one of these letters had been delivered to the wrong address in 2015 only caused a very temporary stir in the media (Bjørn-Hansen 2016).
The Big Data Success Stories
What has the easy access to high quality health data been used for? In this section we can only give some illustrative examples.
A 1997 case-control study of a hypothesized correlation/causal connection between induced abortion and later breast cancer showed conclusively that there was no correlation (Melbye et al. 1997) . It linked data from the civil registration system, the abortion registry, and the cancer registry to form a cohort of 1.5 million women born between 1935 and 1978 of which 280,000 had had one or more induced abortion. The main result was a risk ratio of 1.00 with a 95 per cent confidence interval of 0.94-1.06.
A 2002 case-control study of the very controversial hypothesized correlation/causal connection between combined measles, mumps, and rubella vaccination and the development of autism disconfirmed the correlation (Madsen et al. 2002) . It linked data from five health registries including the vaccination registry and the psychiatric central register to form a cohort of 537,303 children born in 1991-1998 and followed up to the end of 1999. The adjusted relative risk of autistic disorder following vaccination was 0.92 with a 95 per cent confidence interval of 0.68-1.24.
Both these studies provided convincing and timely answers to controversial research questions with very significant public health implications. Because of the near total completeness of the Danish registries and the possibility of easy cross linking without ambiguity because of the use of a single, common identifier, these studies are not affected by recall bias which would otherwise be likely to occur.
A perhaps more controversial use was a 2015 casecontrol study of the link between male childhood circumcision and the development of autism that used similar methods as the two studies described above and found that B … regardless of cultural background circumcized boys were more likely than intact boys to develop ASD before age 10 years (HR = 1.46; 95% CI: 1.11-1.93)^ (Frisch and Simonsen 2015, 266) . Male childhood circumcision is in Denmark almost exclusively performed by Muslims and Jews for religious reasons.
One example of the many studies linking health data with non-health data is a 2014 study on the effect of socioeconomic position on patient outcome after hysterectomy (Daugbjerg et al. 2014) . Here data from the hospital episode register, the hysterectomy clinical quality database, and the integrated database for labour market research are linked and it is found that the patient outcome differs considerably according to employment status at the time of the operation, even when adjusted for risk factors like smoking and obesity and for educational attainment and income.
Bigger Big Data
Each of us intentionally or unintentionally generate large amounts of digital data that are captured and stored by commercial actors including the producers of our wearable devices, telephone companies, internet service providers, Facebook, Amazon, Google, etcetera.
These datasets are hugely commercially valuable-the data mining firm Dunnhumby running the British supermarket chain Tesco's loyalty card scheme was for instance valued at one to two billion USD in 2015 (Maidment 2015) ; and the business models of firms like Google and Facebook are built around monetizing the data that we provide when using their Bfree^services. The data is also very valuable for research, because it provides objective direct information about behaviours and activities that cannot accurately be measured in other ways, and where self-reporting is potentially biased. The future of epidemiology will therefore undoubtedly involve increasing use of these kinds of data. An American working group for the National Heart, Lung and Blood Institute for instance recommended in 2013 that: BThe NHLBI should actively engage in studies to establish the validity, reliability, and scalability of electronic tools for primary data collection ( Roger et al. 2015, 364) .
The future for Big Data health research in Denmark is thus very likely to involve a move from the current position where the data used in the research comes from databases collected and controlled by public authorities, to a mixed economy of data where a large part of the data necessary for research comes from commercial firms, primarily in the ICT sector broadly conceived.
Governance In a Mixed Data Economy
The current Danish governance system for the collection of data about citizens and the later secondary use of stored data for research is, as described above, very liberal; and its continued existence relies on a web of multiple complex relationships of trust. Danish policy makers and regulators trust Danish researchers and most citizens trust researchers and the official authorities.
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These trust relationships rely partly on the belief that the research that is being conducted contributes to the public good. And the trust is maintained partly because there have been no major research-related scandals that could have undermined the trust. Denmark has had its share of scientific misconduct cases, but they have not involved big data research. The trust is not specific and it does not rely on detailed knowledge of the Danish databases or their use. It is general and probably, at its most specific, institutional, i.e. it is a trust vested in Danish official institutions. This general institutional trust is intertwined with a generalized trust of the healthcare professions. In a 2016 Danish survey of the perceived trustworthiness of different professions nurses came on top as the most trustworthy profession, and doctors were ranked as number three after nurses and judges (Radius Kommunikation 2016).
The new mixed data economy introduces a new set of commercial actors to the secondary use of data for research field. The relationship between these actors and their customers or users is usually based on a much more narrow basis of trust, involving a recognition on the part of the customer that the primary goal of the other party may not be Bfurthering the public good^and that it may well try to take commercial advantage of them, either now or in the future.
What are the implications of this new mixed data economy for the governance system? Can a very liberal system with limited governance of individual research projects and no consent requirements for secondary use be sustained?
To answer these questions we need to analyse the future role of commercial actors and the data they hold in more detail, and we need to analyse what interests the governance system should promote and protect.
Commercial actors are going to be involved in Big Data research in a number of different ways. They may be mere data providers, or they may be more involved in the research process as initiators, funders, part of mixed public-private research groups, or conducting research themselves. These different roles raise different governance issues. If the commercial involvement is merely to provide data that are used by public researchers and the data flow is strictly in one direction the primary governance issues are very similar to the issues that arise for the public data sources described above. And, in the Danish context there would be no strong reasons to treat a commercial data source differently in relation to consent or research ethics approval. Issues might however arise in relation to the gatekeeping function of data controllers. The current use of public databases operates on the basis that all bona fide Danish researchers and research groups have access on an equal basis, but commercial data controllers might want to restrict access to certain research groups or certain research questions. A decision would have to be made at the policy level concerning whether such active gatekeeping should be allowed or not.
If commercial actors are both data providers and directly involved in the actual research, more complicated governance issues arise. A two-way flow of data between public and commercial organizations raises the question of the ethical and societal basis and legitimacy of data sharing because of the very different relations that exist between citizens and public institutions and customers and commercial firms respectively. Let us briefly list some of the main elements of difference. The customer's relationship with a commercial data controller is governed by an explicit contract, most often not read or understood by the customer (Bakos, Marotta-Wurgler, and Trossen 2009; Ploug and Holm 2013, 2014) , and the firm owns the data. The primary goal of the firm is not the furtherance of the public good but the long-term economic benefit of its owners. The data controller is, furthermore, not a stable entity but may be transformed by merger, acquisition, bankruptcy, or dissolution and this may make it difficult for data subjects to maintain any knowledge about where there data are held and what is being done with it. There is also very little transparency in how the data are being used as has been evidenced for instance by recurrent controversies about Facebook's use of data (Luckerson 2014; Voosen 2014) . And finally, there is a lack of any democratic legitimacy and very little 2 Danish citizens have the second highest level of trust in their government and public institutions among the E.U. countries, only Finland having higher trust levels. Denmark is one of only seven E.U. countries where more than 50 per cent of citizens trust the government and public institutions (European Commission 2015, 68) . possibility for the customer to influence the policies of the firm in any way. Although the path from the voting booth to the actions of public bodies is long, it is at least in principle possible for citizens to hold public bodies to account through the normal democratic processes.
This creates a governance dilemma. The current governance system is based on the logic of the citizen-state relationship and on a presumption that research that is being conducted is in the public interest and leads to public benefit. But in a mixed data economy we have at least two types of relationships with very different logics in play and it is not obvious that the current very liberal governance system for secondary use of health data can be maintained without modification.
There are three significant risks involved in moving toward a mixed data economy. The first risk is that the general trust in public institutions cannot be sustained if the public becomes worried about the use of data by commercial actors and that this will undermine the core functions of the healthcare system since individuals will be less willing to share the health and other information that is necessary for good diagnosis and treatment. The second risk is that the basis for the current acceptance of secondary use of health data with very limited restrictions and a fairly minimal governance burden may be eroded. And the third and final risk is that data will come to be used in ways that are incompatible with the interests of citizens but that no one realizes this.
Operating a governance regime without any requirements for consent for the secondary use of health data can only be justified if either or both of the following propositions are true 1) citizens can never be harmed by secondary use of health data, 2) the non-harm related interests that individual citizens may have in controlling the use of their health data are always outweighed by the societal interest in promoting research.
However, both propositions are deeply questionable. Even if we discount the possibility of direct individual harm caused by research use of health data, or by misuse of data that were originally released for research, we cannot discount the possibility of group harm indirectly affecting the individual members of a group. Results of research and even the formulation of specific research questions can lead to increased stigmatization of groups, customs, and behaviours. Citizens can also have strong interests in controlling who can use their data and for what purposes, and it is implausible that these are always outweighed by societal interests. These considerations can already be taken to undermine any justification of the current Danish system, but they will become even more pertinent in the future when research will involve data sharing with actors that the public have no particular reason to trust and may actively distrust. It might be possible to argue that there is a separate obligation to participate in public endeavours like public research which should lead citizens to discount their own interests (for a discussion of whether there is a duty to participate in research within a learning healthcare system see Faden et al. 2013 ), or that citizens should contribute based on solidarity with fellow citizens (Prainsack and Buyx 2016) , but such arguments are significantly weakened in a mixed data economy where some of the research activities have private profit as their primary goal.
What should a new governance system look like if we accept: 1) that citizens have legitimate interests in controlling the use of their health and other data and interests in being protected from misuse of their data, 2) we all share an interest in research, audit, and quality improvement aimed at furthering the public good, and 3) that the interests if citizens will become more acute and more complex in the future mixed data economy? There are many tools in the general governance toolbox and many possible governance targets and here we will focus on 1) governance of researchers, 2) governance of projects, and 3) the possibility of data subjects to control the use of their data through some form of consent and/ or withdrawal.
The current Danish governance system checks the bona fides of researchers by authorizing research groups for data access on the basis of the group having the necessary scientific expertise and the necessary infrastructure to ensure technical data safety. The main purpose of this part of the governance system is to ensure that data are only provided to people who have a scientific interest in the data and who know how to analyse them appropriately. A future governance system will need to maintain this level of control but may also have to introduce a Bpublic good^test, i.e. an evaluation of how likely it is that a research group will use data in a way that promotes the public good. Such an evaluation is, as we will discuss below in relation to governance of projects, not easy to make, but it may be necessary because the current underlying presumption that researchers always act in ways that promote the public good (when doing their research) may not be sustainable in relation to a future wider range of commercial research groupings seeking access to health data in order to combine them with data they hold.
There is probably also a role for increased training of researchers in research ethics. This should not just be training about the research ethics rules and regulation but training that enables researchers to reflect more critically on how to balance the interests of research participants/data subjects against other interests and how to design studies that protect the interests of participants as far as possible.
The current Danish governance system has a very light touch approach to the governance of projects as described above. No evaluation of the purposes of a project, its sensitivity, or of the likelihood of public benefit is performed, as long as the use of data in a project is objectively legal. One possible element of a strengthened governance system for a mixed data economy could be to re-introduce a research ethical assessment of projects, while maintaining the position that approved projects can proceed without consent. A re-introduction of REC approval could ensure that it was assessed whether projects create significant risk of group harm in terms of discrimination or stigmatization. Research ethics committee approval could furthermore ensure that all projects reached some minimum level of prospective contribution to the public good and that no project was approved which was on the face of it likely to undermine public trust in research. However, a decision about whether the public good likely to be generated by a project outweighs the interests of citizens in control over their data and thereby justifies research without consent is more complicated than just determining whether a project reaches the minimum level of public good that makes it acceptable to perform. Determination of likely contribution to the public good is notoriously difficult, and would in a mixed data economy become even more difficult if increased prosperity or contribution to the gross domestic product is defined as a public benefit, since most commercially driven research could be (re-)described as having such economic benefits. Apart from interests in the public good produced by health research, individual citizens and groups also, as mentioned above, have potential interests in what kind of research their data is used for. They may have legitimate interests related to the purposes of research projects or to who performs the research. A person could, for instance have an interest in data not being used by researchers funded or employed by the tobacco industry. And some of these individual interests are likely to be shared by larger groups in society and not be merely and strictly individual. It is difficult to see how an ethical assessment leading to either approval or refusal of a project as a whole can protect these more individualized interests. In this context it is important to note that the fact that we all share a general interest in the public good produced by medical research does not in itself indicate 1) how strong this interest is in relation to a specific project, or 2) whether it is outweighed by other interests in the specific case. Re-introducing REC approval will to some extent be able to protect persons against harmful use of their data, but it will not be able to protect their more individualized interests even in the cases where these interests are shared by large groups. This entails that REC approval should be re-introduced in Denmark and that it should not be abolished in other jurisdictions where it is the norm. But the arguments also entail that REC or similar approval is not a complete solution, because it still leaves open the question of when consent is needed.
The standard approach to protecting individualized interests is to seek individual permission, or more specifically in the context of research ethics, individualized consent. In the next section we will therefore analyse the relevance of a range of different consent models as elements of a governance system in a mixed data economy.
Models of Consent
As we have argued above, we do not think that a governance system without any consent requirements is sustainable in a mixed data economy. On the other hand it is unlikely in the Danish context, and probably also in general, that a governance system which requires specific informed consent every time an individual's health or other publically held data are used for research can be implemented. It will be practically very burdensome for researchers, and will not in reality protect the interests of individuals. Each person would receive so many consent requests that they would be unlikely to reflect or be able to reflect on each of them, leading to routinization of consent (Ploug and Holm 2013, 2014) .
In the following we are therefore ignoring the noconsent and specific consent models and focusing our analysis on four alternatives 1) opt-out, 2) broad consent, 3) dynamic consent, and 3) meta-consent.
BOpt-out^/Right To Be Forgotten
Will adequate protection of interests be achieved by granting individuals the right to opt-out of research using their data and/or to have their data deleted. This right may concern all/broad categories of research using health data or it may be relative to a specific research project. This approach allows an individual to protect personal and sensitive information and to act on values relevant to the character of research by withdrawing from research in general or from a specific research project. Although we are here considering a governance system for the use of secondary health data, note that more generally an opt-out model without a right to be forgotten only allows individuals to protect themselves against the use-and not the registration-of personal and sensitive information.
Both the general and specific opt-out variants are faced with problems. The general opt-out model is not sensitive to individual preferences concerning different kinds of research. Although individuals may have an interest in withdrawing from some kinds of research using particular types of data, they may at the same time have an interest in contributing to the public good achieved from other kinds of research. With an all-or-nothing approach there is no sensitivity to such differences in preferences.
If the specific opt-out model should be built on informed choices it requires that individuals be provided with extensive information about the specific research projects in which their data is being used. This raises all the same problems concerning practicality and routinization of decision-making that are raised by a specific consent requirement. Finally, it is worth mentioning that any opt-out model including a Bright to be forgotten,^i.e. a right to have data deleted, is potentially very damaging to research. If people lose their trust in research and researchers they may decide to exercise their right to have their data deleted and thereby create significant holes in the available data. Moreover, since health data is also used for administrative purposes, it is not at all clear that individuals could in practice be given a right to be forgotten encompassing all of their health data.
Broad/Blanket Consent
Another model of consent builds on the idea that individuals should be asked for consent to broad categories of research or to research as such (Hansson et al. 2006; Otlowski 2009) . That is, individuals should be asked to provide open-ended broad or blanket consent to the use of their health data. The model allows in principle for individuals to control both the registration and use of personal and sensitive information and to act on individual values. Furthermore, since individuals only have to make a limited number of choices based on general information about broad categories of research or about research as such, these choices are less likely to become routinized. Finally, it will be less of a hindrance to research than a requirement for specific consent by limiting the number of consent requests that researchers must issue to individuals.
Some have suggested that broad and blanket consent cannot be considered informed consent since an individual's choice is not based on specific information about a given research project in this model (Hofmann 2009 ). However, persons can have an overruling broad preference concerning participation in research. They may, for instance, have a dominant general preference for contributing to certain broad categories of healthcare related research as it is conducted in a particular research context at a given time. In this case information in broad terms about the kind of research will make a choice suitably informed (Helgesson 2012) .
A model of broad/blanket cannot be sensitive to differences in an individual or groups of individuals' preferences concerning different types of research. Similarly to a model of general opt-out it is an all-or-nothing approach that does not allow an individual to express different consent preferences in relation to more specific research projects, i.e. it does not enable individuals to consent to some research projects and refuse consent to others if the research projects fall within the same broad category of research.
Dynamic Consent
The traditional model of informed consent requires informed consent for each specific research project in which an individual's personal data is being collected and used. By providing a choice for each specific research project individuals may, on the basis of specific information about the research project, exercise a very strong control over the collection and use of their personal data, and they may express multi-facetted preferences and views concerning the character and context of research.
However, by requiring individuals to make a choice for each and every research project in which their data is being used there is, as discussed above, significant risk that this choice will become routinized, i.e. provided as an unreflected, habitual act (Ploug and Holm 2013, 2014) or that individuals will simply refuse consent due to Bconsent fatigue^ (Cambon-Thomsen 2004) . Applying Information Technology (IT) in a dynamic consent process may to remedy each of these problems to an extent (Kaye et al. 2015) . Dynamic consent was initially developed as a method for ensuring continued consent in longitudinal cohort and biobank studies where future research uses of the data and tissue collected could not be fully specified at the beginning of the project, but it has later been extended to other contexts.
Key to the dynamic consent model is the idea 1) that a web-based platform provides participants with consent requests when new uses are planned, as well as ongoing information about the use of health data and tissue for research purposes, and 2) that the level of information provided preceding consent requests as well as the amount of feedback from the research should be tailored by choices made by the individual.
If information about research projects are provided online with multiple points of access and individuals are given control over the flow of information in relation to specific research projects, then routinization and consent fatigue seem less likely to occur and the burden on researchers becomes more manageable. Routinization occurs, however, not only as a result of the level of information in relation to research, it also occurs because of the number of research requests put to the individual. Providing individuals with a flexible and dynamic control of information can therefore at best only be a partial solution to these problems.
Meta Consent
The basic idea in the model of meta consent is that individuals should be allowed to express their preference for how and when to provide consent (Ploug and Holm 2015, 2016) . That is, individuals should be given the opportunity to design future consent requests. Designing future consent requests fundamentally consists in pairing types of consent (specific, broad, blanket, blanket refusal) with types of data (Electronic patient records (EPR), Genomic data, Health databases, Other databases etc.) and types of research contexts (Private/Public, Commercial/Non-commercial, National/International etc.), where this choice determines how and when consent requests are put to the individual in the future. An individual pairing of BBroad^and BEPR^thus expresses a preference for being asked for consent in the future to broad categories of research using data from the EPR.
The meta-consent model has a number of merits. It provides an individual with a strong degree of control over the use of personal health data. Thus an individual may require specific consent for all research use of health data. The meta consent model is an effective barrier against routinization since it allows individuals to choose to limit the number of consent requests to a level that they are comfortable with by choosing the Bbroad^or Bblanket^consent options or by refusing use of personal data entirely. The possibility of designing future consent requests may in itself produce a stronger motivation to engage in consent procedures. Finally, the model of meta consent enables efficient research by potentially reducing the number of consent requests that must be put to individuals. In a context, like the Danish where there is a high level of trust in research and researchers there is reason to believe that many individuals will provide broad or blanket consent to research use of their personal healthcare data. Furthermore, the meta-consent model could be combined with a default of Bopt-out.^That is, the model could operate on a default of using data if individuals fail to register their meta-consent preferences. This would make available for research data that would otherwise be unavailable.
The meta-consent model also faces challenges. It requires individuals to design a meta consent and this may turn out to be difficult to achieve at a population level. Also, in order to enable both design and redesign of meta consent in an easy and flexible way, the metaconsent model requires an IT-infrastructure at the national level along with the possibility of effective linkage between various different healthcare databases. Although the implementation of IT systems in public administration is rapidly progressing in many countries in these years, only a few countries-e.g. Denmark and Norway-would currently be able to meet the ITinfrastructure requirements of a meta-consent model. But the very developments that make big data science possible will also over time enable the implementation of meta consent.
We believe that meta consent could be an invaluable part of a future governance system for the secondary research use of health data. It addresses issues of consent across a variety of data types and research contexts. There is little reason to think that the amount of data, the number of data sources, and the number of research projects will diminish in the future. Meta consent constitutes an effective instrument for handling informed consent procedures in an era of Bbig data^research.
Conclusion
The future mixed data economy in health research where data from a variety of public and commercial sources are used in research and audit by both public and commercial actors will require a reconsideration of current governance systems for the secondary research use of routinely collected health and other administrative data. This reconsideration will in most countries be path-dependent because its starting point will not be a clean slate on which an optimal governance system can be sketched but an already existing governance system serving and supported by a range of entrenched interests. Depending on the starting point, considering governance for a mixed data economy may thus lead to liberalization in some jurisdictions and increased protection in others. We have argued that in the Danish context where the current governance system is very liberal, and where there are currently no general consent requirements for the secondary use of health data and no requirement of REC approval, the modifications in the governance system should be aimed at increasing the protection of citizens in their role as data subjects. Researchers should be better trained in research ethics, a requirement for REC approval should be re-introduced, and a meta consent/meta permission model implemented. In jurisdictions that start from a more restrictive position meta consent may also be attractive as a way of balancing researcher interests and the interests of individuals. Implementing a meta-consent system does, however, require an effective underlying IT structure that may not yet exist in many countries.
